"I believe the world is on the verge of an effective Ebola vaccine."
Marie-Paule Kieny, assistant director general of the World Health Organization, announcing positive results for the phase III trial of the Merck & Co. Inc./Newlink Genetics Corp. VSV-EBOV vaccine in Guinea. The ring vaccination study showed VSV-EBOV was 100 percent effective in protecting contacts and contacts of contacts, of patients diagnosed with Ebola infection

"We've got a little bit of a problem in that we've got so many great things going on. With a small team of about 80 people, we're trying to identify the best opportunities."
Marc Hedrick, president and CEO of Cytori Therapeutics Inc., discussing the phase III STAR trial of ECCS-50, the company's adipose-derived regenerative cell therapy, in hand dysfunction caused by scleroderma. The FDA is regulating the cell therapy as a device despite orphan drug designation by the EMA

"This is a natural fit with the rest of our portfolio in hemophilia. We are anticipating an approval from the FDA later this year, as well, with our extended half-life recombinant factor VIII, Adynovate, so we're hoping for two approvals this year and perhaps the first in a series of new product approvals over the next couple of years."
John Orloff, head of research and development and chief scientific officer at Baxalta Inc., discussing the phase III data and already filed biologics license application for BAX 111 (Vonvendi) in the bleeding disorder von Willebrand disease